Eight to twelve Gy linked to less retreatment than 4 Gy in cutaneous B-cell lymphoma
In previously unirradiated cutaneous B-cell lymphoma lesions, one-year freedom from retreatment was 75% after 4 Gy versus 100% after 8–12 Gy.
In previously unirradiated cutaneous B-cell lymphoma lesions, one-year freedom from retreatment was 75% after 4 Gy versus 100% after 8–12 Gy.
Among 82 cutaneous lymphoma patients, 38% prioritized quality of life, while those with Sézary syndrome traveled a median 201 km for RT.
An MTV threshold of 50 mL identified patients with poorer survival who appeared to benefit from combined-modality treatment.
Concurrent polatuzumab vedotin and radiotherapy was feasible in heavily pretreated aggressive B-cell lymphoma without unexpected acute or subacute toxicity.
Three-year locoregional recurrence-free survival was 90.8%, with most locoregional recurrences occurring within or near the radiation field.